BACKGROUND: The possibility to enlarge criteria for intra-peritoneal chemotherapy (IPC) to all patients at high-risk to develop peritoneal carcinosis (i.e., with serosal invasion) is still discussed. METHODS: Retrospective case-control study. Three-groups: advanced-gastric-cancer (AGC) (pT4) without proven carcinosis: prophylactic group (PG), those with PC: treatment group (TG), AGC (pT3-pT4) operated without hyperthermic intraperitoneal chemotherapy (HIPEC), surgery alone group (SG T3, SG T4). RESULTS: Forty four patients. 26 (59.1%) were male. Sixteen (36%) patients underwent 16 HIPEC: 6 (38%) had AGC (pT4) without PC (PG), 10 (62%) had carcinosis (TG), 28 were operated without HIPEC (SG T3, SG T4). The mean disease free survival (DFS): TG: 7.7 months, SG T4: 21.6 months, SG T3: 27.7 months, PG: 34.5 months. DFS was significantly different for TG (P=0.03, P=0.021, P=0.013 respectively). The mean OS TG: 10 months, SG T4: 27.1 months, SG T3: 28.2 months, PG: 34.6 months. OS was significantly different for TG (P=0.04, P=0.04, P=0.045 respectively). Severe complication rate: TG: 60%, PG: 16.7%, SG T3: 7.7% and SG T4: 25% (P=0.035). Length-of-stay differs significantly (P=0.003); overall length-of-stay: 19.41 days [standard deviation (SD) ±15.03]; TG: 33.01 (SD ±23.08), PG: 20.17 (SD ±6.21), SG T3: 11.33 (SD ±3.22), SG T4: 15.36 (SD ±5.48). CONCLUSIONS: Prophylactic intraperitoneal chemotherapy associated to neoadjuvant chemotherapy increases the DFS and OS in patients with AGC without carcinosis. More data are needed in order to confirm these results.
BACKGROUND: The possibility to enlarge criteria for intra-peritoneal chemotherapy (IPC) to all patients at high-risk to develop peritoneal carcinosis (i.e., with serosal invasion) is still discussed. METHODS: Retrospective case-control study. Three-groups: advanced-gastric-cancer (AGC) (pT4) without proven carcinosis: prophylactic group (PG), those with PC: treatment group (TG), AGC (pT3-pT4) operated without hyperthermic intraperitoneal chemotherapy (HIPEC), surgery alone group (SG T3, SG T4). RESULTS: Forty four patients. 26 (59.1%) were male. Sixteen (36%) patients underwent 16 HIPEC: 6 (38%) had AGC (pT4) without PC (PG), 10 (62%) had carcinosis (TG), 28 were operated without HIPEC (SG T3, SG T4). The mean disease free survival (DFS): TG: 7.7 months, SG T4: 21.6 months, SG T3: 27.7 months, PG: 34.5 months. DFS was significantly different for TG (P=0.03, P=0.021, P=0.013 respectively). The mean OSTG: 10 months, SG T4: 27.1 months, SG T3: 28.2 months, PG: 34.6 months. OS was significantly different for TG (P=0.04, P=0.04, P=0.045 respectively). Severe complication rate: TG: 60%, PG: 16.7%, SG T3: 7.7% and SG T4: 25% (P=0.035). Length-of-stay differs significantly (P=0.003); overall length-of-stay: 19.41 days [standard deviation (SD) ±15.03]; TG: 33.01 (SD ±23.08), PG: 20.17 (SD ±6.21), SG T3: 11.33 (SD ±3.22), SG T4: 15.36 (SD ±5.48). CONCLUSIONS: Prophylactic intraperitoneal chemotherapy associated to neoadjuvant chemotherapy increases the DFS and OS in patients with AGC without carcinosis. More data are needed in order to confirm these results.
Authors: F Coccolini; F Catena; O Glehen; Y Yonemura; P H Sugarbaker; P Piso; G Montori; L Ansaloni Journal: Eur J Surg Oncol Date: 2015-04-14 Impact factor: 4.424
Authors: H J Braam; J H Schellens; H Boot; J W van Sandick; C A Knibbe; D Boerma; B van Ramshorst Journal: Crit Rev Oncol Hematol Date: 2015-04-17 Impact factor: 6.312
Authors: Y Yonemura; X de Aretxabala; T Fujimura; S Fushida; K Katayama; E Bandou; K Sugiyama; T Kawamura; K Kinoshita; Y Endou; T Sasaki Journal: Hepatogastroenterology Date: 2001 Nov-Dec
Authors: E Bando; Y Yonemura; Y Takeshita; K Taniguchi; T Yasui; Y Yoshimitsu; S Fushida; T Fujimura; G Nishimura; K Miwa Journal: Am J Surg Date: 1999-09 Impact factor: 2.565
Authors: T Fujimura; Y Yonemura; K Muraoka; H Takamura; Y Hirono; H Sahara; I Ninomiya; H Matsumoto; K Tsugawa; G Nishimura Journal: World J Surg Date: 1994 Jan-Feb Impact factor: 3.352
Authors: K Nakamura; T Ueyama; T Yao; Z X Xuan; K Ambe; Y Adachi; Y Yakeishi; A Matsukuma; M Enjoji Journal: Cancer Date: 1992-09-01 Impact factor: 6.860
Authors: S Bremholm Ellebæk; M Graversen; S Detlefsen; L Lundell; C W Fristrup; P Pfeiffer; M B Mortensen Journal: Clin Exp Metastasis Date: 2020-01-30 Impact factor: 5.150
Authors: Antoine El Asmar; Melissa Bendavides; Michel Moreau; Alain Hendlisz; Amélie Deleporte; Maher Khalife; Vincent Donckier; Gabriel Liberale Journal: World J Surg Oncol Date: 2020-11-26 Impact factor: 2.754